ICLR Stock Price Chart Interactive Chart >

ICLR Price/Volume Stats

ICON plc - Ordinary Shares (ICLR) Company Bio

ICON Public Limited Company provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company was founded in 1990 and is based in Dublin, Ireland.

ICLR Price Forecast Based on DCF Valuation

Below please find a table outlining a discounted cash flow forecast for ICLR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Icon Plc ranked in the 40th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Icon Plc, consider:

• Interest coverage, a measure of earnings relative to interest payments, is 33.02; that's higher than 88.53% of US stocks in the Healthcare sector that have positive free cash flow.
• The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 13.59% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
• ICLR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 45.37% of tickers in our DCF set.

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ICLR, try STE, REGN, GILD, MEDP, and CRL.